Stanozolol
Especificaciones
10418-03-8Número CAS
233-894-8Número CE
(1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-olNombre IUPAC
C21H32N2OFórmula química
328.5 g/molPeso molecular
stanozolol; Winstrol; Androstanazole; 10418-03-8; Androstanazol; Stromba; Stanazolol; Tevabolin; Winstrol Depot; Strombaject; Estazol; Winstrol V; Estanozolol; Winstroid; Stanozololum; WIN 14833; Stanozolol ciii; DTXSID3044128; NSC-43193; WIN-14833; 4R1VB9P8V3; 17-Methyl-2'H-5alpha-androst-2-eno(3,2-c)pyrazol-17beta-ol; NSC-233046; 2'H-Androst-2-eno(3,2-c)pyrazol-17-ol, 17-methyl-, (5alpha,17beta)-; 17-Methyl-5alpha-androstano(3,2-c)pyrazol-17beta-ol; CHEBI:9249; 17beta-Hydroxy-17-methyl-5alpha-androstano(3,2-c)pyrazole; DTXCID1024128; 2'H-5alpha-Androst-2-eno(3,2-c)pyrazol-17beta-ol, 17-methyl-; NSC43193; Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-; Methylstanazol; stanozololo; NSC233046; Winstrol-V Tablets; (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo(11.7.0.0^(2,10).0^(4,8).0^(14,18))icosa-4(8),5-dien-17-ol; (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5-dien-17-ol; RefChem:6260; Winstrol-V Chewable Tablets; Winstrol-V Sterile Suspension; A14AA02; 1'H-ANDROSTANO(3,2-C)PYRAZOL-17-OL, 17-METHYL-, (5alpha,17beta)-; 233-894-8; Anabol; Androstanazolestanazol; NSC 233046; C21H32N2O; (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol; (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol; Stanozolo [DCIT]; Androstanazole (VAN); Stanozolo; Stanozolol (1'H form); Winstrol-V; Stanozololum [INN-Latin]; Estanozolol [INN-Spanish]; Cyclopenta(7,8)phenanthro(2,3-c)pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-; HSDB 3185; SR-05000001522; 302-96-5; Stanozolol (2'H form); EINECS 233-894-8; NSC 43193; UNII-4R1VB9P8V3; MFCD00133084; Stanozolol CRS; 17.BETA.-HYDROXY-17.ALPHA.-METHYL-5.ALPHA.-ANDROSTANO(3,2-C)PYRAZOLE; LKAJKIOFIWVMDJ-IYRCEVNGSA-N; Winstrol (TN); Stanozolol degrees; WIN14833; Stanozolol [USAN:USP:INN:BAN:JAN]; 17-beta-Hydroxy-17-alpha-methylandrostano(3,2-c)pyrazole; 17beta-Hydroxy-17alpha-methyl-androstano(3,2-c)pyrazole; 17-Methyl-pyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol; 17-Methylpyrazolo(4',3':2,3)-5alpha-androstan-17beta-ol; A1IOS; STANOZOLOL [MI]; STANOZOLOL [INN]; STANOZOLOL [JAN]; 2,3-(4',3'-Pyrazolo)-5alpha-androstan-17beta-ol, 17-methyl-; STANOZOLOL [HSDB]; STANOZOLOL [USAN]; STANOZOLOL [VANDF]; STANOZOLOL [MART.]; STANOZOLOL [WHO-DD]; SCHEMBL44099; SCHEMBL44101; Stanozolol (JAN/USP/INN); 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-Hexadecahydro-1,10a,12a-trimethylcyclopenta(7,8)-phenanthro(2,3-c)pyrazol-1-ol; MLS001424321; 17-Methyl-2'H-5.alpha.-androst-2-eno(3,2-c)pyrazol-17.beta.-ol; Stanozolol, analytical standard; STANOZOLOL [GREEN BOOK]; CHEMBL2079587; STANOZOLOL [ORANGE BOOK]; GTPL10369; STANOZOLOL [EP MONOGRAPH]; STANOZOLOL CIII [USP-RS]; GLXC-10566; HMS2052H11; HMS2090P03; HMS3713K06; STANOZOLOL [USP MONOGRAPH]; HY-B0899; Stanozolol, 1mg/ml in Acetonitrile; Tox21_113993; MSK8501-100A; s7701; 1'H-Androstano(3,2-c)pyrazol-17-ol, 17-methyl-, (5-alpha,17-beta)-; AKOS005067278; MSK8501-1000A; Stanozolol 1.0 mg/ml in Acetonitrile; CCG-101186; CCG-220452; CS-4363; DB06718; NC00436; NCGC00344550-01; NCGC00344550-04; (1S,3aS,3bR,5aS,10aS,10bS,12aS)-1,10a,12a-trimethyl-1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-ol; AC-16140; AC-33164; AS-35198; CPD000058878; FS156771; SMR000058878; CAS-10418-03-8; NS00008736; C07311; D00444; Stanozolol Solution in Acetonitrile, 100ug/mL; 17-Methyl-5a-androstano[3,2-c]pyrazol-17b-ol; AB00443942-03; AB00443942-05; Stanozolol Solution in Acetonitrile, 1000ug/mL; SR-05000001522-1; SR-05000001522-2; 17a-Methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole; 17b-Hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole; 17b-Hydroxy-17a-methyl-5a-androstano[3,2-c]pyrazole; BRD-K46791647-001-01-2; Q63409446; 17-Methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol; Stanozolol, European Pharmacopoeia (EP) Reference Standard; (5a,17b)-17-methyl-2'H-Androst-2-eno[3,2-c]pyrazol-17-ol; 2,3'-Pyrazolo)-5.alpha.-androstan-17.beta.-ol, 17-methyl-; 17-METHYL-5.ALPHA.-ANDROSTANO(3,2-C)PYRAZOL-17.BETA.-OL; 2'H-5a-Androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8CI); 17alpha-Methyl-17beta-hydroxy-5alpha-androst-2-eno(3,2-c)-pyrazole; 1'H-ANDROSTANO(3,2-C)PYRAZOL-17-OL, 17-METHYL-, (5.ALPHA.,17.BETA.)-; 2'H-ANDROST-2-ENO(3,2-C)PYRAZOL-17-OL, 17-METHYL-, (5.ALPHA.,17.BETA.); Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazol-17-ol deriv.; 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-Cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol; Cyclopenta[7,3-c]pyrazol-1-ol, 1,2,3,3a,3b,4,5,5a,6,8,10,10a,10b,11,12,12a-hexadecahydro-1,10a,12a-trimethyl-Sinónimos
